JP2006511620A5 - - Google Patents

Download PDF

Info

Publication number
JP2006511620A5
JP2006511620A5 JP2005508486A JP2005508486A JP2006511620A5 JP 2006511620 A5 JP2006511620 A5 JP 2006511620A5 JP 2005508486 A JP2005508486 A JP 2005508486A JP 2005508486 A JP2005508486 A JP 2005508486A JP 2006511620 A5 JP2006511620 A5 JP 2006511620A5
Authority
JP
Japan
Prior art keywords
antibody
pharmaceutical formulation
preparation according
pharmaceutical
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2005508486A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006511620A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/038809 external-priority patent/WO2004052397A1/en
Publication of JP2006511620A publication Critical patent/JP2006511620A/ja
Publication of JP2006511620A5 publication Critical patent/JP2006511620A5/ja
Pending legal-status Critical Current

Links

JP2005508486A 2002-12-05 2003-12-05 抗cd3抗体による潰瘍性大腸炎の処置方法 Pending JP2006511620A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43164902P 2002-12-05 2002-12-05
US45018303P 2003-02-25 2003-02-25
PCT/US2003/038809 WO2004052397A1 (en) 2002-12-05 2003-12-05 Methods of treatment of ulcerative colitis with anti-cd3 antibodies

Publications (2)

Publication Number Publication Date
JP2006511620A JP2006511620A (ja) 2006-04-06
JP2006511620A5 true JP2006511620A5 (enExample) 2007-01-25

Family

ID=32511592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2005508486A Pending JP2006511620A (ja) 2002-12-05 2003-12-05 抗cd3抗体による潰瘍性大腸炎の処置方法

Country Status (7)

Country Link
US (1) US20040253237A1 (enExample)
EP (1) EP1567192A4 (enExample)
JP (1) JP2006511620A (enExample)
KR (1) KR20050091713A (enExample)
AU (1) AU2003298015A1 (enExample)
CA (1) CA2508264A1 (enExample)
WO (1) WO2004052397A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005048935A2 (en) * 2003-11-14 2005-06-02 Brigham And Women's Hospital, Inc. Methods of modulating immunity
ES2526343T3 (es) 2004-06-03 2015-01-09 Novimmune Sa Anticuerpos anti-CD3 y métodos de uso de los mismos
WO2007026742A1 (ja) * 2005-08-30 2007-03-08 Ajinomoto Co., Inc. 大腸デリバリー型炎症性大腸疾患治療薬
US20100209437A1 (en) * 2005-09-12 2010-08-19 Greg Elson Anti-CD3 Antibody Fromulations
AU2012201443B2 (en) * 2006-06-06 2014-04-03 Glaxo Group Limited Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
JP2009539841A (ja) * 2006-06-06 2009-11-19 トラークス,インコーポレイテッド 自己免疫疾患の治療における抗cd3抗体の投与
LT2647707T (lt) 2010-11-30 2018-11-12 Chugai Seiyaku Kabushiki Kaisha Citotoksiškumą indukuojantis terapinis agentas
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018144999A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
US20210138213A1 (en) * 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
CN116726362A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
CN118562007A (zh) * 2019-12-19 2024-08-30 苏州方德门达新药开发有限公司 工程改造的t细胞、其制备及应用
US12122850B2 (en) 2022-03-14 2024-10-22 LamKap Bio gamma AG Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
DE19905012A1 (de) * 1999-02-08 2000-08-10 Gsf Forschungszentrum Umwelt Arzneimittel enthaltend Anti-CD3- und Anti-Fcgamma-R-Antikörper zur begleitenden Behandlung bei Organtransplantationen
CN101745112A (zh) * 2002-07-19 2010-06-23 艾博特生物技术有限公司 TNFα相关疾病的治疗

Similar Documents

Publication Publication Date Title
JP2006511620A5 (enExample)
JP7293122B2 (ja) 補体が媒介する疾患および障害を処置するための方法
TWI306458B (en) Humanized antibodies that recognize beta amyloid peptide
CN111068062B (zh) 治疗白介素-6相关疾病的方法
JP2020536888A5 (enExample)
JP2020537644A5 (enExample)
JP2021502961A5 (enExample)
JP2014114288A5 (enExample)
JP2003501401A (ja) B細胞をターゲットとする抗体を使用する自己免疫疾患に対する免疫療法
JPWO2020059847A5 (enExample)
JP2021531255A (ja) 非古典的hla−iおよびネオアンチゲンを含む複合体を標的とする抗体、およびその使用方法
JP2013519690A5 (enExample)
JP2024528640A (ja) 癌処置の組合せ薬
JPWO2020018922A5 (enExample)
JPWO2019186273A5 (enExample)
WO2018226833A1 (en) Methods of suppressing microglial activation
US20230227555A1 (en) Cd-3 antibodies for the treatment of coronavirus
US20240109977A1 (en) Anti-cd38 antibodies and their uses
JP2024507986A (ja) 抗体関連型移植拒絶反応の治療に使用するための抗cd38抗体
EP3937978A1 (en) A method for immunosuppression
JP2008531719A5 (enExample)
JP2019519470A5 (enExample)
JPWO2021171002A5 (enExample)
CN116635422A (zh) 抗cd38抗体及其用途
NZ749153A9 (en) Anti-c5 antibodies and uses thereof